Turkiye Klinikleri Journal of Veterinary Sciences

.: REVIEW
Beşeri ve Veteriner Hekimlikte Onkolitik Viroterapi
Oncolytic Virotherapy in Human and Veterinary Medicine
Erdem GÜLERSOYa, Mutlu SEVİNÇa, Mahmut OKa
aKonya Selçuk Üniversitesi Veteriner Fakültesi, İç Hastalıkları ABD, Konya, TÜRKİYE
Turkiye Klinikleri J Vet Sci. 2020;11(2):69-80
doi: 10.5336/vetsci.2020-78253
Article Language: TR
Full Text
ÖZET
 Gen terapisi stratejileri olarak adlandırılan tedavi seçenekleri, çeşitli kanser olgularında kullanılan yeni tedavi yaklaşımlarıdır. Bu yeni tedavi yaklaşımlarından biri olan onkolitik viroterapi, en umut vaat edici anti-kanser ajanı olarak kabul edilmektedir. Uygulanan tedavi etkileri, intratümöral amplifikasyon ve sitosidal aktiviteler şeklindedir. Onkolitik viroterapi, CTLA-4 ve PD-1 proteinlere bağlanan ve bloke eden immün kontrol noktası inhibitörleri ile başarılı kanser tedavisinden sonraki muhtemelen en önemli kanser tedavisi gelişimidir. Virüs bazlı tedavilerde güvenlik oldukça önemlidir. Onkolitik virüsler genetik olarak geliştirilmiş veya normal dokuya hasar vermeden seçici bir şekilde kanserli hücrede replike olup hücreyi öldüren doğal virüsler olarak tanımlanırlar. Granülosit-makrofaj koloni uyarıcı faktör ile güçlendirilmiş ikinci jenerasyon onkolitik Herpes Simplex Virus Tip-1 (T-Vec; Talimogene laherparapvec), Amerika Birleşik Devletleri ve Avrupa'da Food and Drug Administration tarafından onaylanmış ilk onkolitik viral ilaçtır. Faz III denemeleri, T-Vec enjekte edilmiş tümörlerin küçüldüğünü ve kanserli hastanın yaşam süresini uzattığını göstermiştir. Kuzey Amerika ve Avrupa'da onay çalışmaları devam eden diğer onkolitik aşı virüsleri Pexastimogene devacirepvec, Adenovirus CG0070 ve Reovirus'tur. Bunların dışında tümör spesifik viral replikasyona sahip ve kanserli hastanın yaşam süresini uzatan pek çok onkolitik virüs klinik denemelere dâhil edilmiştir. Hızla gelişen teknoloji ve artan klinik çalışmalar sebebiyle yakın zamanda onkolitik viroterapinin hem beşeri hem de veteriner hekimlikte tüm kanser hastaları için standart terapötik bir prosedür olması oldukça muhtemeldir.

Anahtar Kelimeler: Onkolitik viroterapi; kanin distemper virüs; adenovirus; newcastle disease virus; reovirus
ABSTRACT
 Treatment options such as gene therapy strategies are new treatment approaches used in various cancer cases. Oncolytic virotherapy, one of these new treatment approaches, is recognized as the most promising anti-cancer agent. The applied treatment effects are intratumoral amplification and cytocidal activities. Oncolytic virotherapy is probably the most important development in cancer treatment after successful cancer treatment with immune checkpoint inhibitors that bind and block CTLA-4 and PD-1 proteins. Safety is very important in virus-based treatments. Oncolytic viruses are defined as genetically engineered or natural occurring viruses that selectively replicate the cancerous cell and kill the cell without damaging normal tissue. The second generation oncolytic herpes simplex virus type-1 (TVec; Talimogene laherparapvec), powered by granulocyte-macrophage colony stimulating factor, is the first oncolytic viral drug approved in the United States and Europe by Food and Drug Administration. Phase III trials have shown that T-Vec injected tumors shrink and prolong the life of the cancer patient. Other oncolytic vaccine viruses whose approval studies ongoing in North America and Europe are Pexastimogene devacirepvec, Adenovirus CG0070 and Reovirus. Apart from these, many oncolytic viruses with tumor-specific viral replication and prolonging the life of the cancer patient were included in clinical studies. Due to the rapidly developing technology and increasing clinical studies, oncolytic virotherapy is likely to be a standard therapeutic procedure for all cancer patients in both human and veterinary medicine.

Keywords: Oncolytic virotherapy; canine distemper virus; adenovirus; newcastle disease virus; reovirus
REFERENCES:
  1. Hall NC, Zhang J, Povoski SP, Martin EW, Knopp MV. New developments in imaging and functional biomarker technology for the assessment and management of cancer patients. Expert Rev Med Devices. 2009;6(4):347-51.[Crossref] [PubMed] 
  2. Yamamoto M. Conditionally replicative adenovirus for gastrointestinal cancers. Expert Opin Biol Ther. 2004;4(8):1241-50.[Crossref] [PubMed] 
  3. Andtbacka RH, Kaufman HL, Collichio F, Amatruda T, Senzer N, Chesney J, et al. Talimogene Laherparepvec Improves Durable Response Rate in Patients With Advanced Melanoma. J Clin Oncol. 2015;33(25):2780-8.[Crossref] [PubMed] 
  4. Billeter MA, Naim HY, Udem SA. Reverse genetics of measles virus and resulting multivalent recombinant vaccines: applications of recombinant measles viruses. Curr Top Microbiol Immunol. 2009;329:129-62.[Crossref] [PubMed] [PMC] 
  5. Breitbach CJ, Paterson JM, Lemay CG, Falls TJ, McGuire A, Parato KA, et al. Targeted inflammation during oncolytic virus therapy severely compromises tumor blood flow. Mol Ther. 2007;15(9):1686-93.[Crossref] [PubMed] 
  6. Gentschev I, Ehrig K, Donat U, Hess M, Rudolph S, Chen N, et al. Significant Growth Inhibition of Canine mammary carcinoma xenografts following treatment with oncolytic vaccinia virus GLV-1h68. J Oncol. 2010;20(10):736907.[Crossref] [PubMed] [PMC] 
  7. Gordon S. Alternative activation of macrophages. Nat Rev Immunol. 2003;3(1):23-35.[Crossref] [PubMed] 
  8. Sgadari C, Angiolillo AL, Tosato G. Inhibition of angiogenesis by interleukin-12 is mediated by the interferon-inducible protein 10 Blood. 1996;87(9):3877-82.[Crossref] [PubMed] 
  9. Zygiert Z. Hodgkin's disease: remissions after measles. Lancet. 1971;1(7699):593.[Crossref] [PubMed] 
  10. Peng KW, Holler PD, Orr BA, Kranz DM, Russell SJ. Targeting virus entry and membrane fusion through specific peptide/MHC complexes using a high-affinity T-cell receptor Gene Ther. 2004;11(15):1234-9.[Crossref] [PubMed] 
  11. Leonard VH, Hodge G, Reyes-Del Valle J, McChesney MB, Cattaneo R. Measles virus selectively blind to signaling lymphocytic activation molecule (SLAM; CD150) is attenuated and induces strong adaptive immune responses in rhesus monkeys. J Virol. 2010;84(7):3413-20.[Crossref] [PubMed] [PMC] 
  12. Noyce RS, Delpeut S, Richardson CD. Dog nectin-4 is an epithelial cell receptor for canine distemper virus that facilitates virus entry and syncytia formation. Virology. 2013;436(1):210-20.[Crossref] [PubMed] 
  13. Hwang CC, Igase M, Sakurai M, Haraguchi T, Tani K, Itamoto K, et al. Oncolytic reovirus therapy: Pilot study in dogs with spontaneously occurring tumours. Vet Comp Oncol. 2018;16(2):229-38.[Crossref] [PubMed] 
  14. Takano A, Ishikawa N, Nishino R, Masuda K, Yasui W, Inai K, et al. Identification of nectin-4 oncoprotein as a diagnostic and therapeutic target for lung cancer. Cancer Res. 2009;69(16):6694-703.[Crossref] [PubMed] 
  15. Woo PC, Lau SK, Wong BH, Fan RY, Wong AY, Zhang AJ, et al. Feline morbillivirus, a previously undescribed paramyxovirus associated with tubulointerstitial nephritis in domestic cats. Proc Natl Acad Sci USA. 2012;109(14):5435-40.[Crossref] [PubMed] [PMC] 
  16. Maes P, Amarasinghe GK, Ayllón MA, Basler CF, Bavari S, Kuhn JH, et al. Taxonomy of the order Mononegavirales: second update 2018. Arch Virol. 2019;164(4):1233-44.[Crossref] [PubMed] [PMC] 
  17. Gülersoy E, Ok M, Sevinç M, Durgut MK, Naseri AA. [Case of A 13-Year-Old Dog with Old Dog Encephalitis: A Rare Form of Canine Distemper]. Kocatepe Vet J. 2020;13(2):224-7.
  18. Qiu W, Zheng Y, Zhang S, Fan Q, Liu H, Zhang F, et al. Canine distemper outbreak in rhesus monkeys, China. Emerg Infect Dis. 2011;17(8):1541-3.[Crossref] [PubMed] [PMC] 
  19. Sakai K, Nagata N, Ami Y, Seki F, Suzaki Y, Iwata-Yoshikawa N, et al. Lethal canine distemper virus outbreak in cynomolgus monkeys in Japan in 2008. J Virol. 2013;87(2):1105-14.[Crossref] [PubMed] [PMC] 
  20. Martinez-Gutierrez M, Ruiz-Saenz J. Diversity of susceptible hosts in canine distemper virus infection: a systematic review and data synthesis. BMC Vet Res. 2016;12:78.[Crossref] [PubMed] [PMC] 
  21. Hartley WJ. A post-vaccinal inclusion body encephalitis in dogs. Vet Pathol. 1974;11(4):301-12.[Crossref] [PubMed] 
  22. Carpenter JW, Appel MJ, Erickson RC, Novilla MN. Fatal vaccine-induced canine distemper virus infection in black-footed ferrets. J Am Vet Med Assoc. 1976;169(9):961-4.[PubMed] 
  23. McInnes EF, Burroughs RE, Duncan NM. Possible vaccine-induced canine distemper in a South American bush dog (Speothos venaticus). J Wildl Dis. 1992;28(4):614-7.[Crossref] [PubMed] 
  24. Sutherland-Smith MR, Rideout BA, Mikolon AB, Appel MJ, Morris PJ, Shima AL, et al. Vaccine-induced canine distemper in European mink, Mustela lutreola. J Zoo Wildl Med. 1997;28(3):312-8.[PubMed] 
  25. Martella V, Blixenkrone-Møller M, Elia G, Lucente MS, Cirone F, Decaro N, et al. Lights and shades on an historical vaccine canine distemper virus, the Rockborn strain. Vaccine. 2011;29(6):1222-7.[Crossref] [PubMed] 
  26. Suter SE, Chein MB, von Messling V, Yip B, Cattaneo R, Vernau W, et al. In vitro canine distemper virus infection of canine lymphoid cells: a prelude to oncolytic therapy for lymphoma. Clin Cancer Res. 2005;11(4):1579-87.[Crossref] [PubMed] 
  27. Garcia JA, Ferreira HL, Vieira FV, Gameiro R, Andrade AL, Eugênio FR, et al. Tumour necrosis factor-alpha-induced protein 8 (TNFAIP8) expression associated with cell survival and death in cancer cell lines infected with canine distemper virus. Vet Comp Oncol. 2017;15(2):336-44.[Crossref] [PubMed] 
  28. Del Puerto HL, Martins AS, Milsted A, Souza-Fagundes EM, Braz GF, Hissa B, et al. Canine distemper virus induces apoptosis in cervical tumor derived cell lines. Virol J. 2011;8:334.[Crossref] [PubMed] [PMC] 
  29. Li P, Wang J, Chen G, Zhang X, Lin D, Zhou Y, et al. Oncolytic activity of canine distemper virus in canine mammary tubular adenocarcinoma cells. Vet Comp Oncol. 2019;17(2):174-83.[Crossref] [PubMed] 
  30. Gassen U, Collins FM, Duprex WP, Rima BK. Establishment of a rescue system for canine distemper virus. J Virol. 2000;74(22):10737-44.[Crossref] [PubMed] [PMC] 
  31. von Messling V, Zimmer G, Herrler G, Haas L, Cattaneo R. The hemagglutinin of canine distemper virus determines tropism and cytopathogenicity. J Virol. 2001;75(14):6418-27.[Crossref] [PubMed] [PMC] 
  32. Buchholz UJ, Finke S, Conzelmann KK. Generation of bovine respiratory syncytial virus (BRSV) from cDNA: BRSV NS2 is not essential for virus replication in tissue culture, and the human RSV leader region acts as a functional BRSV genome promoter. J Virol. 1999;73(1):251-9.[Crossref] [PubMed] [PMC] 
  33. Anderson DE, von Messling V. Region between the canine distemper virus M and F genes modulates virulence by controlling fusion protein expression. J Virol. 2008;82(21):10510-8.[Crossref] [PubMed] [PMC] 
  34. Elroy-Stein O, Moss B. Cytoplasmic expression system based on constitutive synthesis of bacteriophage T7 RNA polymerase in mammalian cells. Proc Natl Acad Sci USA. 1990;87(17):6743-7.[Crossref] [PubMed] [PMC] 
  35. Beaty SM, Park A, Won ST, Hong P, Lyons M, Vigant F, et al. Efficient and Robust Paramyxoviridae Reverse Genetics Systems. mSphere. 2017;2(2):e00376-16.[Crossref] [PubMed] [PMC] 
  36. Martin A, Staeheli P, Schneider U. RNA polymerase II-controlled expression of antigenomic RNA enhances the rescue efficacies of two different members of the Mononegavirales independently of the site of viral genome replication. J Virol. 2006;80(12):5708-15.[Crossref] [PubMed] [PMC] 
  37. Ludlow M, Nguyen DT, Silin D, Lyubomska O, de Vries RD, von Messling V, et al. Recombinant canine distemper virus strain Snyder Hill expressing green or red fluorescent proteins causes meningoencephalitis in the ferret. J Virol. 2012;86(14):7508-19.[Crossref] [PubMed] [PMC] 
  38. Tatsuo H, Ono N, Yanagi Y. Morbilliviruses use signaling lymphocyte activation molecules (CD150) as cellular receptors. J Virol. 2001;75(13):5842-50.[Crossref] [PubMed] [PMC] 
  39. Pratakpiriya W, Ping Teh AP, Radtanakatikanon A, Pirarat N, Thi Lan N, Takeda M, et al. Expression of canine distemper virus receptor nectin-4 in the central nervous system of dogs. Sci Rep. 2017;7(1):349.[Crossref] [PubMed] [PMC] 
  40. Bieringer M, Han JW, Kendl S, Khosravi M, Plattet P, Schneider-Schaulies J. Experimental adaptation of wild-type canine distemper virus (CDV) to the human entry receptor CD150. PLoS One. 2013;8(3):e57488.[Crossref] [PubMed] [PMC] 
  41. de Vries RD, Ludlow M, Verburgh RJ, van Amerongen G, Yüksel S, Nguyen DT, et al. Measles vaccination of nonhuman primates provides partial protection against infection with canine distemper virus. J Virol. 2014;88(8):4423-33.[Crossref] [PubMed] [PMC] 
  42. Backhaus PS, Veinalde R, Hartmann L, Dunder JE, Jeworowski LM, Albert J, et al. Immunological effects and viral gene expression determine the efficacy of oncolytic measles vaccines encoding IL-12 or IL-15 agonists. Viruses. 2019;11(10):914.[Crossref] [PubMed] [PMC] 
  43. Shenk T. Adenoviridae: the viruses and their replication. In: Fields BN, Knipe DM, Howley PM, editors. Fields virology. Vol. 2. Lippincott-Raven; Philadelphia, PA; 1996. p. 2111-48.
  44. Killock D. Skin cancer: T-VEC oncolytic viral therapy shows promise in melanoma. Nat Rev Clin Oncol. 2015;12(8):438.[Crossref] [PubMed] 
  45. Bischoff JR, Kirn DH, Williams A, Heise C, Horn S, Muna M, et al. An adenovirus mutant that replicates selectively in p53-deficient human tumor cells. Science. 1996;274(5286):373-6.[Crossref] [PubMed] 
  46. LaRocca CJ, Han J, Salzwedel AO, Davydova J, Herzberg MC, Gopalakrishnan R, et al. Oncolytic adenoviruses targeted to human papilloma virus-positive head and neck squamous cell carcinomas. Oral Oncol. 2016;56:25-31.[Crossref] [PubMed] [PMC] 
  47. Stoff-Khalili MA, Rivera AA, Nedeljkovic-Kurepa A, DeBenedetti A, Li XL, Odaka Y, et al. Cancer-specific targeting of a conditionally replicative adenovirus using mRNA translational control. Breast Cancer Res Treat. 2008;108(1):43-55.[Crossref] [PubMed] [PMC] 
  48. Wesseling JG, Bosma PJ, Krasnykh V, Kashentseva EA, Blackwell JL, Reynolds PN, et al. Improved gene transfer efficiency to primary and established human pancreatic carcinoma target cells via epidermal growth factor receptor and integrin-targeted adenoviral vectors. Gene Ther. 2001;8(13):969-76.[Crossref] [PubMed] 
  49. Nukui Y, Picozzi VJ, Traverso LW. Interferon-based adjuvant chemoradiation therapy improves survival after pancreaticoduodenectomy for pancreatic adenocarcinoma. Am J Surg. 2000;179(5):367-71.[Crossref] [PubMed] 
  50. Hsu KF, Wu CL, Huang SC, Hsieh JL, Huang YS, Chen YF, et al. Conditionally replicating E1B-deleted adenovirus driven by the squamous cell carcinoma antigen 2 promoter for uterine cervical cancer therapy. Cancer Gene Ther. 2008;15(8):526-34.[Crossref] [PubMed] 
  51. Dias JD, Hemminki O, Diaconu I, Hirvinen M, Bonetti A, Guse K, et al. Targeted cancer immunotherapy with oncolytic adenovirus coding for a fully human monoclonal antibody specific for CTLA-4. Gene Ther. 2012;19(10):988-98.[Crossref] [PubMed] 
  52. Belshe RB, Edwards KM, Vesikari T, Black SV, Walker RE, Hultquist M, et al.; CAIV-T Comparative Efficacy Study Group. Live attenuated versus inactivated influenza vaccine in infants and young children. N Engl J Med. 2007;356(7):685-96.[Crossref] [PubMed] 
  53. Bukreyev A, Collins PL. Newcastle disease virus as a vaccine vector for humans. Curr Opin Mol Ther. 2008;10(1):46-55.[PubMed] 
  54. Samal SK. Newcastle disease and related avian paramyxoviruses. In: The Biology of Paramyxoviruses; Norfolk, UK: Caister Academic Press; 2011. p.69-114.
  55. Peeters BP, de Leeuw OS, Koch G, Gielkens AL. Rescue of Newcastle disease virus from cloned cDNA: evidence that cleavability of the fusion protein is a major determinant for virulence. J Virol. 1999;73(6):5001-9.[Crossref] [PubMed] [PMC] 
  56. Panda A, Huang Z, Elankumaran S, Rockemann DD, Samal SK. Role of fusion protein cleavage site in the virulence of Newcastle disease virus. Microb Pathog. 2004;36(1):1-10.[Crossref] [PubMed] [PMC] 
  57. Bukreyev A, Huang Z, Yang L, Elankumaran S, St Claire M, Murphy BR, et al. Recombinant newcastle disease virus expressing a foreign viral antigen is attenuated and highly immunogenic in primates. J Virol. 2005;79(21):13275-84.[Crossref] [PubMed] [PMC] 
  58. Nakaya T, Cros J, Park MS, Nakaya Y, Zheng H, Sagrera A, et al. Recombinant Newcastle disease virus as a vaccine vector. J Virol. 2001;75(23):11868-73.[Crossref] [PubMed] [PMC] 
  59. Miest TS, Cattaneo R. New viruses for cancer therapy: meeting clinical needs. Nat Rev Microbiol. 2014;12(1):23-34.[Crossref] [PubMed] [PMC] 
  60. Zhao X, Chester C, Rajasekaran N, He Z, Kohrt HE. Strategic Combinations: The Future of Oncolytic Virotherapy with Reovirus. Mol Cancer Ther. 2016;15(5):767-73.[Crossref] [PubMed] 
  61. van Houdt WJ, Smakman N, van den Wollenberg DJ, Emmink BL, Veenendaal LM, van Diest PJ, et al. Transient infection of freshly isolated human colorectal tumor cells by reovirus T3D intermediate subviral particles. Cancer Gene Ther. 2008;15(5):284-92.[Crossref] [PubMed] 
  62. Thirukkumaran CM, Shi ZQ, Luider J, Kopciuk K, Gao H, Bahlis N, et al. Reovirus as a viable therapeutic option for the treatment of multiple myeloma. Clin Cancer Res. 2012;18(18):4962-72.[Crossref] [PubMed] 
  63. Pfankuche VM, Spitzbarth I, Lapp S, Ulrich R, Deschl U, Kalkuhl A, et al. Reduced angiogenic gene expression in morbillivirus-triggered oncolysis in a translational model for histiocytic sarcoma. J Cell Mol Med. 2017;21(4):816-30.[Crossref] [PubMed] [PMC] 
  64. Fukuhara H, Ino Y, Todo T. Oncolytic virus therapy: A new era of cancer treatment at dawn. Cancer Sci. 2016;107(10):1373-9.[Crossref] [PubMed] [PMC] 

.: Up To Date

Login

 Forgot your password?

 New Registration  

Contact

Ortadoğu Reklam Tanıtım Yayıncılık Turizm Eğitim İnşaat Sanayi ve Ticaret A.Ş.

.: Address

Turkocagi Caddesi No:30 06520 Balgat / ANKARA
Phone: +90 312 286 56 56
Fax: +90 312 220 04 70
E-mail: info@turkiyeklinikleri.com

.: Manuscript Editing Department

Phone: +90 312 286 56 56/ 2
E-mail: yaziisleri@turkiyeklinikleri.com

.: English Language Redaction

Phone: +90 312 286 56 56/ 145
E-mail: tkyayindestek@turkiyeklinikleri.com

.: Marketing Sales-Project Department

Phone: +90 312 286 56 56/ 142
E-mail: reklam@turkiyeklinikleri.com

.: Subscription and Public Relations Department

Phone: +90 312 286 56 56/ 118
E-mail: abone@turkiyeklinikleri.com

.: Customer Services

Phone: +90 312 286 56 56/ 118
E-mail: satisdestek@turkiyeklinikleri.com

1. TERMS OF USE

1.1. To use the web pages with http://www.turkiyeklinikleri.com domain name or the websites reached through the sub domain names attached to the domain name (They will be collectively referred as "SITE"), please read the conditions below. If you do not accept these terms, please cease to use the "SITE." "SITE" owner reserves the right to change the information on the website, forms, contents, the "SITE," "SITE" terms of use anytime they want.

1.2. The owner of the "SITE" is Ortadoğu Advertisement Presentation Publishing Tourism Education Architecture Industry and Trade Inc. (From now on it is going to be referred as "Turkiye Klinikleri", shortly) and it resides at Turkocagi cad. No:30, 06520 Balgat Ankara. The services in the "SITE" are provided by "Turkiye Klinikleri."

1.3. Anyone accessing the "SITE" with or without a fee whether they are a natural person or a legal identity is considered to agree these terms of use. In this contract hereby, "Turkiye Klinikleri" may change the stated terms anytime. These changes will be published in the "SITE" periodically and they will be valid when they are published. Any natural person or legal identity benefiting from and reaching to the "SITE" are considered to be agreed to any change on hereby contract terms done by "Turkiye Klinikleri."

1.4. The "Terms of Use" hereby is published in the website with the last change on March 30th 2014 and the "SITE" is activated by enabling the access to everyone. The "Terms of Use" hereby is also a part of the any "USER Contract" was and/or will be done with the users using "Turkiye Klinikleri" services with or without a fee an inseparable.

2. DEFINITIONS

2.1. "SITE": A website offering different kind of services and context with a certain frame determined by "Turkiye Klinikleri" and it is accessible on-line on http://www.turkiyeklinikleri.com domain name and/or subdomains connected to the domain name.

2.2. USER: A natural person or a legal identity accessing to the "SITE" through online settings.

2.3. LINK: A link enabling to access to another website through the "SITE", the files, the context or through another website to the "SITE", the files and the context.

2.4. CONTEXT: Any visual, literary and auditory images published in the "Turkiye Klinikleri", "SITE" and/or any website or any accessible information, file, picture, number/figures, price, etc.

2.5. "USER CONTRACT": An electronically signed contract between a natural or a legal identity benefiting from special services "Turkiye Klinikleri" will provide and "Turkiye Klinikleri".

3. SCOPE OF THE SERVICES

3.1. "Turkiye Klinikleri" is completely free to determine the scope and quality of the services via the "SITE".

3.2. To benefit the services of "Turkiye Klinikleri" "SITE", the "USER" must deliver the features that will be specified by "Turkiye Klinikleri". "Turkiye Klinikleri" may change this necessity any time single-sided.

3.3. Not for a limited number, the services "Turkiye Klinikleri" will provide through the "SITE" for a certain price or for free are;

- Providing scientific articles, books and informative publications for health industry.

- Providing structural, statistical and editorial support to article preparation stage for scientific journals.

4. GENERAL PROVISIONS

4.1. "Turkiye Klinikleri" is completely free to determine which of the services and contents provided in the "SITE" will be charged.

4.2. People benefiting from the services provided by "Turkiye Klinikleri" and using the website can use the "SITE" only according to the law and only for personal reasons. Users have the criminal and civil liability for every process and action they take in the "SITE". Every USER agrees, declares and undertakes that they will not proceed by any function or action infringement of rights of "Turkiye Klinikleri"s and/or other third parties', they are the exclusive right holder on usage, processing, storage, made public and revealing any written, visual or auditory information reported to Turkiye Klinikleri" and/or "SITE" to the third parties. "USER" agrees and undertakes that s/he will not duplicate, copy, distribute, process, the pictures, text, visual and auditory images, video clips, files, databases, catalogs and lists within the "SITE", s/he will not be using these actions or with other ways to compete with "Turkiye Klinikleri", directly or indirectly.

4.3. The services provided and the context published within the "SITE" by third parties is not under the responsibility of "Turkiye Klinikleri", institutions collaborated with "Turkiye Klinikleri", "Turkiye Klinikleri" employee and directors, "Turkiye Klinikleri" authorized salespeople. Commitment to accuracy and legality of the published information, context, visual and auditory images provided by any third party are under the full responsibility of the third party. "Turkiye Klinikleri" does not promise and guarantee the safety, accuracy and legality of the services and context provided by a third party.

4.4. "USER"s cannot act against "Turkiye Klinikleri", other "USER"s and third parties by using the "SITE". "Turkiye Klinikleri" has no direct and/or indirect responsibility for any damage a third party suffered or will suffer regarding "USER"s actions on the "SITE" against the rules of the hereby "Terms of Use" and the law.

4.5. "USER"s accept and undertake that the information and context they provided to the "SITE" are accurate and legal. "Turkiye Klinikleri" is not liable and responsible for promising and guaranteeing the verification of the information and context transmitted to "Turkiye Klinikleri" by the "USER"s, or uploaded, changed and provided through the "SITE" by them and whether these information are safe, accurate and legal.

4.6. "USER"s agree and undertake that they will not perform any action leading to unfair competition, weakening the personal and commercial credit of "Turkiye Klinikleri" and a third party,  encroaching and attacking on personal rights within the "SITE" in accordance with the Turkish Commercial Code Law.

4.7. "Turkiye Klinikleri" reserves the right to change the services and the context within the "SITE"  anytime. "Turkiye Klinikleri" may use this right without any notification and timelessly. "USER"s have to make the changes and/or corrections "Turkiye Klinikleri" required immediately. Any changes and/or corrections that are required by "Turkiye Klinikleri", may be made by "Turkiye Klinikleri" when needed. Any harm, criminal and civil liability resulted or will result from changes and/or corrections required by "Turkiye Klinikleri" and were not made on time by the "USER"s belongs completely to the users.

4.8. "Turkiye Klinikleri" may give links through the "SITE" to other websites and/or "CONTEXT"s and/or folders that are outside of their control and owned and run by third parties. These links are provided for ease of reference only and do not hold qualification for support the respective web SITE or the admin or declaration or guarantee for the information inside. "Turkiye Klinikleri" does not hold any responsibility over the web-sites connected through the links on the "SITE", folders and context, the services or products on the websites provided through these links or their context.

4.9. "Turkiye Klinikleri" may use the information provided to them by the "USERS" through the "SITE" in line with the terms of the "PRIVACY POLICY" and "USER CONTRACT". It may process the information or classify and save them on a database. "Turkiye Klinikleri" may also use the USER's or visitor's identity, address, e-mail address, phone number, IP number, which sections of the "SITE" they visited, domain type, browser type, date and time information to provide statistical evaluation and customized services.

5. PROPRIETARY RIGHTS

5.1. The information accessed through this "SITE" or provided by the users legally and all the elements (including but not limited to design, text, image, html code and other codes) of the "SITE" (all of them will be called as studies tied to "Turkiye Klinikleri"s copyrights) belongs to "Turkiye Klinikleri". Users do not have the right to resell, process, share, distribute, display or give someone permission to access or to use the "Turkiye Klinikleri" services, "Turkiye Klinikleri" information and the products under copyright protection by "Turkiye Klinikleri". Within hereby "Terms of Use" unless explicitly permitted by "Turkiye Klinikleri" nobody can reproduce, process, distribute or produce or prepare any study from those under "Turkiye Klinikleri" copyright protection.

5.2. Within hereby "Terms of Use", "Turkiye Klinikleri" reserves the rights for "Turkiye Klinikleri" services, "Turkiye Klinikleri" information, the products associated with "Turkiye Klinikleri" copyrights, "Turkiye Klinikleri" trademarks, "Turkiye Klinikleri" trade looks or its all rights for other entity and information it has through this website unless it is explicitly authorized by "Turkiye Klinikleri".

6. CHANGES IN THE TERMS OF USE

"Turkiye Klinikleri" in its sole discretion may change the hereby "Terms of Use" anytime announcing within the "SITE". The changed terms of the hereby "Terms of Use" will become valid when they are announced. Hereby "Terms of Use" cannot be changed by unilateral declarations of users.

7. FORCE MAJEURE

"Turkiye Klinikleri" is not responsible for executing late or never of this hereby "Terms of Use", privacy policy and "USER Contract" in any situation legally taken into account as force majeure. Being late or failure of performance or non-defaulting of this and similar cases like this will not be the case from the viewpoint of "Turkiye Klinikleri", and "Turkiye Klinikleri" will not have any damage liability for these situations. "Force majeure" term will be regarded as outside of the concerned party's reasonable control and any situation that "Turkiye Klinikleri" cannot prevent even though it shows due diligence. Also, force majeure situations include but not limited to natural disasters, rebellion, war, strike, communication problems, infrastructure and internet failure, power cut and bad weather conditions.

8. LAW AND AUTHORISATION TO FOLLOW

Turkish Law will be applied in practicing, interpreting the hereby "Terms of Use" and managing the emerging legal relationships within this "Terms of Use" in case of finding element of foreignness, except for the rules of Turkish conflict of laws. Ankara Courts and Enforcement Offices are entitled in any controversy happened or may happen due to hereby contract.

9. CLOSING AND AGREEMENT

Hereby "Terms of Use" come into force when announced in the "SITE" by "Turkiye Klinikleri". The users are regarded to agree to hereby contract terms by using the "SITE". "Turkiye Klinikleri" may change the contract terms and the changes will be come into force by specifying the version number and the date of change on time it is published in the "SITE".

 

30.03.2014

Privacy Policy

We recommend you to read the terms of use below before you visit our website. In case you agree these terms, following our rules will be to your favor. Please read our Terms of Use thoroughly.

www.turkiyeklinikleri.com website belongs to Ortadoğu Advertisement Presentation Publishing Tourism Education Architecture Industry and Trade Inc. and is designed in order to inform physicians in the field of health

www.turkiyeklinikleri.com cannot reach to user’s identity, address, service providers or other information. The users may send this information to the website through forms if they would like to. However, www.turkiyeklinikleri.com may collect your hardware and software information. The information consists of your IP address, browser type, operating system, domain name, access time, and related websites. www.turkiyeklinikleri.com cannot sell the provided user information (your name, e-mail address, home and work address, phone number) to the third parties, publish it publicly, or keep it in the website. Gathered information has a directing feature to be a source for the website’s visitor profile, reporting and promotion of the services.

www.turkiyeklinikleri.com uses the taken information:

-To enhance, improve and maintain the quality of the website

-To generate visitor’s profile and statistical data

-To determine the tendency of the visitors on using our website

-To send print publications/correspondences

-To send press releases or notifications through e-mail

-To generate a list for an event or competition

By using www.turkiyeklinikleri.com you are considered to agree that;

-Ortadoğu Advertisement Presentation Publishing Tourism Education Architecture Industry and Trade Inc. cannot be hold responsible for any user’s illegal and immoral behavior,

-Terms of use may change from time to time,

-It is not responsible for other websites’ contents it cannot control or the harms they may cause although it uses the connection they provided.

Ortadoğu Advertisement Presentation Publishing Tourism Education Architecture Industry and Trade Inc. may block the website to users in the following events:

-Information with wrong, incomplete, deceiving or immoral expressions is recorded to the website,

-Proclamation, advertisement, announcement, libelous expressions are used against natural person or legal identity,

-During various attacks to the website,

-Disruption of the website because of a virus.

Written, visual and audible materials of the website, including the code and the software are under protection by legal legislation.

Without the written consent of Ortadoğu Advertisement Presentation Publishing Tourism Education Architecture Industry and Trade Inc. the information on the website cannot be downloaded, changed, reproduced, copied, republished, posted or distributed.

All rights of the software and the design of the website belong to Ortadoğu Advertisement Presentation Publishing Tourism Education Architecture Industry and Trade Inc.

Ortadoğu Advertisement Presentation Publishing Tourism Education Architecture Industry and Trade Inc. will be pleased to hear your comments about our terms of use. Please share the subjects you think may enrich our website or if there is any problem regarding our website.

info@turkiyeklinikleri.com